» Articles » PMID: 34261459

Patients and General Practitioners Assessment of the Main Outcomes Employed in the Acute and Preventive Treatment of Migraine: a Cross Sectional Study

Overview
Journal BMC Neurol
Publisher Biomed Central
Specialty Neurology
Date 2021 Jul 15
PMID 34261459
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We aim to describe and compare patients and general practitioners' opinions about the different variables related to acute and preventive treatment for migraine.

Patients And Methods: An observational descriptive study was performed. Patients with episodic migraine and general practitioners, from our healthcare area, were invited to answer a survey about the different variables related to migraine treatment. They were asked for their opinions on the different variables, and to consider the desired efficacy in percentage terms and the desired action times of treatment.

Results: Fifty-five patients and fifty-five general practitioners were selected. Effectiveness was considered the most important variable for symptomatic and preventive treatment. Cost was considered the least important variable. Patients desired percentage of efficacy was 84.0% (±16.7%) for symptomatic treatment and 79.9% (±17.1%) for preventive treatment. General practitioners desired percentage of efficacy was 75.0% (±14.0) for symptomatic treatment and 70.4% (±14.3) for preventive treatment. For symptomatic treatment the desired action time for pain cessation was selected as 27.5 min (±13.8) for patients and 24.0 min (±18.3) for GPs. For preventive treatment the desired action time for effect was 7.1 days (±4.5) for patients and 13.9 days (±8.9) for general practitioners.

Conclusion: The most important endpoints were, for acute: effectiveness, a short action time and a persistent effect. For prophylactic: effectiveness, sustained effect and tolerability. Both patients and general practitioners agreed on the most and least preferred endpoints. Desired percentage of efficacy was above 75% for both symptomatic and preventive treatment; and the desired action time was below 30 min for acute treatment and 2 weeks for preventive treatment.

Citing Articles

Early Improvements With Atogepant for the Preventive Treatment of Migraine: Results From 3 Randomized Phase 3 Trials.

Lipton R, Gandhi P, Tassorelli C, Reuter U, Harriott A, Holle-Lee D Neurology. 2024; 104(2):e210212.

PMID: 39715475 PMC: 11668519. DOI: 10.1212/WNL.0000000000210212.


Long-Term Use of Rimegepant 75 mg for the Acute Treatment of Migraine is Associated with a Reduction in the Utilization of Select Analgesics and Antiemetics.

Fullerton T, Pixton G J Pain Res. 2024; 17:1751-1760.

PMID: 38764606 PMC: 11102748. DOI: 10.2147/JPR.S456006.


Beyond pain control: Outcome and treatment preferences in pediatric migraine.

Khayata M, Farley S, Davis J, Hornik C, Reeve B, Rikhi A Headache. 2022; 62(5):588-595.

PMID: 35524445 PMC: 9133183. DOI: 10.1111/head.14315.

References
1.
Cameron C, Kelly S, Hsieh S, Murphy M, Chen L, Kotb A . Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache. 2015; 55 Suppl 4:221-35. DOI: 10.1111/head.12601. View

2.
Shapiro R . Preventive treatment of migraine. Headache. 2012; 52 Suppl 2:65-9. DOI: 10.1111/j.1526-4610.2012.02242.x. View

3.
Shamliyan T, Choi J, Ramakrishnan R, Miller J, Wang S, Taylor F . Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med. 2013; 28(9):1225-37. PMC: 3744311. DOI: 10.1007/s11606-013-2433-1. View

4.
Dodick D, Edvinsson L, Makino T, Grisold W, Sakai F, Jensen R . Vancouver Declaration on Global Headache Patient Advocacy 2018. Cephalalgia. 2018; 38(13):1899-1909. DOI: 10.1177/0333102418781644. View

5.
Mitsikostas D, Belesioti I, Arvaniti C, Mitropoulou E, Deligianni C, Kasioti E . Patients' preferences for headache acute and preventive treatment. J Headache Pain. 2017; 18(1):102. PMC: 5630539. DOI: 10.1186/s10194-017-0813-3. View